首页> RMD open> Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.

导出 LinkOut

翻译打印收藏纠错

第一作者： Niels W,Boone

第一单位： Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, Sittard-Geleen - Heerlen, The Netherlands.

作者： Niels W,Boone ^[1] ; Alexandre,Sepriano ^[2] ; Paul-Hugo,van der Kuy ^[3] ; Rob,Janknegt ^[1] ; Ralph,Peeters ^[4] ; Robert B M,Landewé ^[5]

作者单位： Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, Sittard-Geleen - Heerlen, The Netherlands. ^[1] Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.;NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal. ^[2] Department of Clinical Pharmacy, Erasmus Medical Centre, Rotterdam, The Netherlands. ^[3] Department of Rheumatology, Zuyderland Medical Centre, Sittard-Geleen - Heerlen, The Netherlands. ^[4] Department of Rheumatology, Zuyderland Medical Centre, Sittard-Geleen - Heerlen, The Netherlands.;Amsterdam Rheumatology, and Immunology Centre, Amsterdam, The Netherlands. ^[5]

关键词 DAS28 DMARDs (biologic)methotrexate patient reported outcome measure (PROM)rheumatoid arthritis